Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827973 | 0.95 | PKM (0.61) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6923994 | 0.90 | PKM (0.53) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6922338 | 0.89 | POLB (0.56) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL3069679 | 0.87 | ALDH1A1 (0.54) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6827768 | 0.85 | ALDH1A1 (0.57) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6929713 | 0.85 | ALDH1A1 (0.60) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6920069 | 0.84 | ALDH1A1 (0.49) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6925435 | 0.84 | ALDH1A1 (0.55) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6923759 | 0.84 | POLB (0.57) | PKMRAB9APOLBALDH1A1LMNA | |
| SCHEMBL6925728 | 0.83 | ALDH1A1 (0.56) | PKMRAB9APOLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004073619-A2 | CCR8 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. | 2010-10-28 | — | — | US | disclosed |
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-1922313-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| WO-2004073619-A2 | CCR8 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA3 | PKM 3023/4885RAB9A 1848/4885POLB 1496/4885 |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PKM 2646/4885RAB9A 2395/4885POLB 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.